πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12186367

Isoform Nell-1 peptide

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186368

Compositions and methods for treatment of protease mediated disease

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186330

Compositions for improving cell viability and methods of use thereof

Amylyx Pharmaceuticals, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186369

Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, i

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186324

Imidazopiperazine inhibitors of transcription activating proteins

The Board of Regents of the University of Texas System Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186314

Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced

Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186378

Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonists

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186282

Treatment of 22Q11.2 deletion syndrome with cannabidiol

Harmony Biosciences Management, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12188017

Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186342

Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, I

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186375

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

BIOVERATIV THERAPEUTICS INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186349

Compositions and methods for C. difficile treatment

Regents of the University of Minnesota Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186384

Compositions and methods for making and using thermostable immunogenic formulations with i

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187698

Crystalline forms of C21H22Cl2N4O2

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12188048

Restimulation of cryopreserved tumor infiltrating lymphocytes

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187777

Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186313

Pyridazinone compounds and their use as DAAO inhibitors

Takeda Pharmaceutical Company Limited Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187762

Dithiolsaccharide mucolytic agents and uses thereof

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187769

Cell

AUTOLUS LIMITED Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187772

IL10 agonists and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186285

Compositions and methods of treatment for tinea pedis

Compass Therapeutics LLC Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186306

Methods of treatment for cystic fibrosis

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187779

Anti-human papillomavirus 16 E6 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12187799

Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

The Board of Regents of the University of Texas System Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted